Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21597430 | 0.77 | ALOX5 (0.44) | NPSR1ALDH1A1TSHRTDP1MAPT | |
| Ethylene SCHEMBL6469102 | 0.76 | NPSR1 (0.58) | NPSR1ALDH1A1POLBTSHRTDP1 | |
| SCHEMBL27458234 | 0.76 | ALDH1A1 (0.60) | NPSR1ALDH1A1TSHRTDP1L3MBTL1 | |
| SCHEMBL12471441 | 0.76 | NPSR1 (0.46) | NPSR1ALDH1A1POLBTSHRL3MBTL1 | |
| SCHEMBL8325081 | 0.76 | ESR1 (0.42) | NPSR1ALDH1A1TDP1L3MBTL1MAPT | |
| SCHEMBL28237283 | 0.75 | NPSR1 (0.50) | NPSR1ALDH1A1POLBTSHRTDP1 | |
| SCHEMBL28148401 | 0.75 | NPSR1 (0.64) | NPSR1ALDH1A1POLBTSHRTDP1 | |
| SCHEMBL764342 | 0.75 | NPSR1 (0.50) | NPSR1ALDH1A1POLBTSHRTDP1 | |
| SCHEMBL75885 | 0.75 | NPSR1 (0.64) | NPSR1ALDH1A1POLBTSHRTDP1 | |
| SCHEMBL75883 | 0.75 | NPSR1 (0.64) | NPSR1ALDH1A1POLBTSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1301527-A2 | PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | CORVAS INTERNATIONAL, INC. (US) | 2003-04-16 | — | — | EP | claimed |
| US-20020068702-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | DENDREON PHARMACEUTICALS, INC. | 2002-06-06 | — | — | US | claimed |
| WO-2002008251-A2 | PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | CORVAS INTERNATIONAL, INC. (US) | 2002-01-31 | — | — | WO | claimed |
| EP-0858455-A4 | 4-OXA AND 4-THIA STEROIDS | MERCK & CO INC (US) | 2000-04-12 | — | — | EP | claimed |
| US-5998464-A | 4-Oxa and 4-thia steroids | MERCK & CO., INC. (US) | 1999-12-07 | — | — | US | claimed |
| US-5817802-A | IN IONIZING MEDIUM WITH A TRIALKYLSILANE | MERCK & CO., INC. (US) | 1998-10-06 | — | — | US | claimed |
| EP-0858455-A1 | 4-OXA AND 4-THIA STEROIDS | Merck & Co., Inc. (US) | 1998-08-19 | — | — | EP | claimed |
| US-5777134-A | 4-oxa and 4-thia steriods | MERCK & CO., INC. (US) | 1998-07-07 | — | — | US | claimed |
| US-5696266-A | HYDROGENATING DELTA-5-STEROIDAL ENELACTAM DISSOLVED IN SOLVENT IN PRESENCE OF RHODIUM CATALYST | MERCK & CO., INC. (US) | 1997-12-09 | — | — | US | claimed |
| WO-1997015564-A1 | 4-OXA AND 4-THIA STEROIDS | MERCK & CO., INC. (US) | 1997-05-01 | — | — | WO | claimed |
| WO-1996007643-A1 | PROCESS FOR THE STEREOSELECTIVE REDUCTION OF STEROID ENELACTAMS | MERCK & CO., INC. (US) | 1996-03-14 | — | — | WO | claimed |
| US-20080269247-A1 | Chemokine Inhibiting Piperazine Derivatives and Their Use to Treat Myocarditis | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-10-30 | — | — | US | disclosed |
| US-20080119471-A1 | Piperazine urea derivatives for the treatment of endometriosis | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-05-22 | — | — | US | disclosed |
| CN-101090723-A | Piperazine urea derivatives for the treatment of endometriosis | SCHERING AG (DE) | 2007-12-19 | — | — | CN | disclosed |
| US-7268140-B2 | Piperazine derivatives and their use as anti-inflammatory agents | SCHERING AG (DE) | 2007-09-11 | — | — | US | disclosed |
| US-5696266-A | HYDROGENATING DELTA-5-STEROIDAL ENELACTAM DISSOLVED IN SOLVENT IN PRESENCE OF RHODIUM CATALYST | MERCK & CO., INC. (US) | 1997-12-09 | — | — | US | disclosed |
| WO-1997015305-A1 | TREATMENT OF HYPERANDROGENIC CONDITIONS | MERCK & CO., INC. (US) | 1997-05-01 | — | — | WO | disclosed |
| WO-1997015564-A1 | 4-OXA AND 4-THIA STEROIDS | MERCK & CO., INC. (US) | 1997-05-01 | — | — | WO | disclosed |
| WO-1996007643-A1 | PROCESS FOR THE STEREOSELECTIVE REDUCTION OF STEROID ENELACTAMS | MERCK & CO., INC. (US) | 1996-03-14 | — | — | WO | disclosed |
| EP-0561252-A1 | 2-Oxoquinoline derivatives as angiotensin II antagonists | MERCK PATENT GmbH (DE) | 1993-09-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020068702-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | VIP, TMPRSS15, TMPRSS11D | NPSR1 2661/4885ALDH1A1 2589/4885POLB 4360/4885 |
| US-20080269247-A1 | Chemokine Inhibiting Piperazine Derivatives and Their Use to Treat Myocarditis | CCL2, CCR2, CXCL10 | NPSR1 159/4885ALDH1A1 1361/4885POLB 2640/4885 |
| US-20080119471-A1 | Piperazine urea derivatives for the treatment of endometriosis | ESR2, GPER1, SLC14A1 | NPSR1 721/4885ALDH1A1 306/4885POLB 1427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.